Publication
Optimal, Interpretable, and Personalized Immune Checkpoint Inhibitor Duration in Non-Small Cell Lung Cancer: A Multicenter Real-World Study.
Siqi Wang, Jianhua Liu, Qiang Nie, Ruichuan Shi, Nan Xu, Qianqian He, Guanchao Ye, Jingyi Liu, Qiuyang Hou, Kexue Deng, Lu Wang, Taixue An, Anyi An, Xiujuan Qu, Jiangdian Song
- Source
- PubMed
- Retrieved
- Oct 1, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20261001-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
The optimal treatment duration of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) remains undefined. We conducted a multicenter retrospective cohort study of 1054 patients with NSCLC treated with ICIs across six hospitals in China and one in the United States. Using a…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Lung Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available